Image Courtesy of Guerbet
November 19, 2104 —Guerbet will present its two latest contrast agents, Dotarem (gadoterate meglumine) injection and Lipiodol (ethiodized oil) injection, at the 100th annual Radiological Society of North America (RSNA) Nov. 30 through Dec. 6 in Chicago.
In addition to its exhibit, five abstracts from studies, for which Guerbet provided financial support, have been accepted by RSNA for this year's meeting.
Dotarem (gadoterate meglumine) injection is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain, spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier and/or abnormal vascularity. It received U.S. Food and Drug Administration approval in March 2013. As of Aug. 31, 2014 there have been more than 48 million Dotarem doses administered worldwide.
For more information: www.guerbet.com
April 29, 2026 
